Global Immunology Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed by the World’s Leading Biopharma Companies Since 2016
DUBLIN, Nov. 17, 2023 /PRNewswire/ — The “Immunology Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering.
Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of immunology deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter Highlights
The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.
Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016Browse immunology collaboration and licensing dealsBenchmark analysis – identify market value of transactionsFinancials terms – upfront, milestone, royaltiesDirectory of deals by company A-Z, therapy focus and technology typeLeading deals by valueMost active dealmakersIdentify assets and deal terms for each transactionAccess contract documents – insights into deal structuresDue diligence – assess suitability of your proposed deal terms for partner companiesSave hundreds of hours of research time
Immunology Collaboration and Licensing Deals includes:
Trends in immunology dealmaking in the biopharma industryOverview of collaboration and licensing deal structureDirectory of immunology deal records covering pharmaceutical and biotechnologyThe leading immunology deals by valueMost active immunology licensing dealmakers
In Immunology Collaboration and Licensing Deals, the available deals are listed by:
Company A-ZHeadline valueTherapeutic areaTechnology type
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How are sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in immunology dealmaking
2.1. Introduction
2.2. Immunology partnering over the years
2.3. Immunology partnering by deal type
2.4. Immunology partnering by industry sector
2.5. Immunology partnering by stage of development
2.6. Immunology partnering by technology type
2.7. Immunology partnering by therapeutic indication
Chapter 3 – Financial deal terms for immunology partnering
3.1. Introduction
3.2. Disclosed financials terms for immunology partnering
3.3. Immunology partnering headline values
3.4. Immunology deal upfront payments
3.5. Immunology deal milestone payments
3.6. Immunology royalty rates
Chapter 4 – Leading immunology deals and dealmakers
4.1. Introduction
4.2. Most active in immunology partnering
4.3. List of most active dealmakers in immunology
4.4. Top immunology deals by value
Chapter 5 – Immunology contract document directory
5.1. Introduction
5.2. Immunology partnering deals where contract document available
Chapter 6 – Immunology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by immunology therapeutic target
Deal Directory
Deal directory – Immunology deals by company A-Z 2016 to 2023
Deal directory – Immunology deals by technology type 2016 to 2023
For more information about this report visit https://www.researchandmarkets.com/r/amkv9h
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
You may also like
Juewei brand meat and vegetable products recalled due to Listeria monocytogenes
OTTAWA, ON, April 28, 2024 /CNW/ – Product: Meat and vegetable products Issue: Food – M
Carson Wealth Expands East: $180M Firm Paves the Way for Growth in New Hampshire and Vermont
OMAHA, Neb., Feb. 1, 2024 /PRNewswire/ — Carson Wealth is expanding into the East with the add
The Institute of Human Genetics, Polish Academy of Sciences (IHG PAS) is Live on SOPHiA GENETICS
The SOPHiA DDM™ Platform used by IHG PAS to advance its research of male infertility BOSTON and RO
